Anti-Human CXCL13 Recombinant Antibody (MAb 5378) (CAT#: TAB-107MZ)

Figure 1 Epitope Competition ELISA results for MAb 5378, MAb 5261, and MAb 470.

Figure 2 Specificity ELISA results for MAb 5378, 3D2, and Mouse Isotype Control binding to recombinant human (A), cynomolgus monkey (B) and mouse (C) CXCL13.

Each data point represents mean of triplicate measurements. EC50 values were calculated from four-parameter sigmoidal curve fit (curves are shown on the graph; R for the curves that produced EC50 values were 0.99).

Figure 3 Percent Inhibition of human pre-B-697-hCXCR5 (A), human tonsillar cells (B) and C57Black6 mouse spleenocyte (C) migration by MAb 5261 or MAb 5378 (A-B) and MAb 5378 or 3D2 (C).

Data represent an average of triplicate measurements +/- SEM from one of at least three experiments. Curves were fitted using four-parameter sigmoidal curve fit (curves are shown on the graph; R = 0.99).

Figure 4 Percent Inhibition of human CXCL13-mediated internalization of human CXCR5 receptor by MAb 5378, MAb 5261, 3D2, Mouse Isotype Control, or Human Isotype Control.

Data points for 5261 and 5378 represent average of measurements from two independent experiments. Data points for 3D2 and Isotype Controls represent average of triplicate measurements from a single experiment. Curve was fitted using four-parameter sigmoidal curve fit (curves are shown on the graph; R2 = 0.99). NE = no effect.

Figure 5 Collagen-induced arthritis (CIA) disease progression in mice treated with MAb 5376, etanercept, or Mouse IgG (control) (CIA-1 Study).

Each data point represents a mean of scores taken from 10 mice. Group means were compared by using one-way ANOVA followed by Bonferroni's multiple comparison post test.

Figure 6 Collagen-induced arthritis (CIA) disease progression in mice treated with MAb 5378, etanercept, MAb 470, or Mouse IgG (control) (CIA-2 Study).

Each data point represents a mean of scores taken from 10 mice. Group means were compared by using one-way ANOVA followed by Bonferroni's multiple comparison post test.